AtriCure (US.ATRC)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.ATRC · YoY: 2026 H1 vs 2025 H1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 58.1% | ↑ |
| ROE | 1.8% | ↑ |
| Cash Conversion | 200.8% | → |
| D/E Ratio | 0.14 | ↑ |
| Gross Margin | 77.3% | → |
US.ATRC (AtriCure) | YoY: 2026 H1 vs 2025 H1 Metric Value YoY ---------------------------- FCF Conversion 58.1% ↑ ROE 1.8% ↑ Cash Conversion 200.8% → D/E Ratio 0.14 ↑ Gross Margin 77.3% →
Key Metrics
US.ATRC (AtriCure) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY----------------------------FCF Conversion 58.1% ↑ROE 1.8% ↑Cash Conversion 200.8% →D/E Ratio 0.14 ↑Gross Margin 77.3% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies